Martin K. Till, New President and CEO of HNL Lab Medicine, Starts with Strategic Plan to Accelerate Growth
HNL Lab Medicine, a regional leader in high quality, innovative laboratory medicine services, announces the official start of Martin K. Till as president and CEO, transitioning from Matthew R. Sorrentino, Esq., who will retire Oct. 15 and continue in a consulting capacity for the next year. Till and Sorrentino have been working together for the last couple of months to ensure a smooth transition and get fiscal year 2022 strategic planning underway to ensure a strong vision for growth.
Till, who was the former chair of the HNL Lab Medicine board of directors and served as vice chairman of the Lehigh Valley Health Network board of trustees, has resigned both board appointments upon assuming his new position as president and CEO of HNL Lab Medicine.
Kathrine O’Brien, who previously was vice chair of the HNL Lab Medicine board with Till, is now the sole chair. A retired consumer marketing executive, she serves on the boards of directors at Lehigh Valley Health Network, Tabula Rasa Healthcare, Cosmetic Executive Women and AMAG Pharmaceuticals.
Till brings a broad range of business experience to his new position, including media, real estate and technology.
“Martin Till’s rich experience with the business, customers and internal teams at both HNL Lab Medicine, and with our largest partner LVHN, makes him the ideal next leader of this fast-growing company,” O’Brien said. “His entrepreneurial spirit combined with his 15 years of involvement in every facet of HNL Lab Medicine’s work prepare him well for the significant opportunities we have to contribute further to the health of people and communities in the Lehigh Valley and beyond.”
Sorrentino’s involvement with both HNL Lab Medicine and LVHN goes back nearly 25 years, including serving as outside counsel for both organizations and as LVHN’s senior vice president and chief legal officer.
As a founder of HNL Lab Medicine and throughout the years leading up to his becoming president and CEO in 2019, he played a key role in its impressive reach – establishing more than 60 locations – and in making an ongoing impact in community health.
“Matt’s leadership, dedication and passion for HNL Lab Medicine have been exemplary, especially during the COVID-19 pandemic when he led innovations and overcame supply shortages to ensure the company could meet the unprecedented needs of people and customers,” O’Brien said. “On behalf of the board and the teams at HNL Lab Medicine, we are grateful to Matt for his vision and execution in establishing HNL Lab Medicine as the regional leader in this highly competitive and dynamic business of laboratory medicine.”
Sorrentino will remain a consultant to both HNL Lab Medicine and LVHN and continue his work in the community